Equity Profile

IDXX

IDEXX Laboratories, Inc.

Health CareHealth Care Equipment$44.5B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

IDEXX Laboratories, Inc. is a leading provider of diagnostic products and services for the veterinary, livestock, and poultry markets....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and growth potential, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and product offerings, crucial for sustaining long-term growth.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IDXX Q2-2026 Earnings Preview

Context

Company Snapshot

IDEXX Laboratories, Inc. is a leading provider of diagnostic products and services for the veterinary, livestock, and poultry markets. As part of the Health Care sector, IDEXX plays a crucial role in animal health, which is increasingly important as pet ownership rises and the demand for quality veterinary care grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+2.46%

Avg Stock Reaction

+6.39%

Last Quarter Recap

In Q1-2026, IDEXX reported an EPS of $3.47, exceeding estimates by 1.49%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Focus on expanding product lines in veterinary diagnostics.
Commitment to enhancing customer service and support.
Plans to invest in research and development for innovative solutions.

Expectations

Wall Street Expectations

Overall expectations for IDEXX's upcoming earnings are mixed, with investors looking for signs of continued growth in a competitive market.

Bull Case

If IDEXX can demonstrate strong revenue growth and maintain or improve its EPS, it could signal robust demand for its products, leading to a positive market reaction.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported revenue growth in the veterinary diagnostics segment?

This metric is crucial as it directly impacts overall profitability and investor confidence in IDEXX's growth trajectory.

Will the EPS exceed $3.50?

Exceeding this EPS threshold could indicate strong operational performance and boost market sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate IDEXX's ability to leverage its innovative product pipeline, which could drive higher-than-expected revenue growth this quarter.

Supporting Evidence

The company's recent investments in R&D are likely to yield new products that could boost sales.

Historical performance shows a strong beat rate of 75%, indicating a tendency to exceed expectations.

Options pricing suggests a significant move, which may indicate that traders are anticipating a positive surprise.

Key Risk

If veterinary diagnostic sales exceed expectations, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around IDEXX's ability to maintain growth in a competitive market while managing costs effectively.

Bull Confirmed If

Revenue growth of over 10% year-over-year would confirm the bull case.

Bear Confirmed If

Any revenue decline or stagnant growth would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±17.90%

Historical Avg

±10.0%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect notable volatility around the earnings announcement.

Options are pricing ±17.9% while IDXX has averaged ±10.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

31.3%

Calls (3K)P/C Ratio: 2.14Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If IDEXX beats expectations, history suggests a potential stock increase of around +8.77%, confirming strong demand and operational efficiency.

In-Line / Cautious

An in-line report may lead to a muted reaction, with investors closely analyzing management's commentary for future guidance.

Miss

If the company misses expectations, history suggests a potential decline of around -0.73%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches in the veterinary diagnostics space.
2Any commentary on market share changes or competitive dynamics.
3Insights into cost management strategies and their impact on margins.
4Details on customer feedback regarding recent product innovations.
5Guidance on future revenue expectations and growth strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul31

SONYBMO

Sony Group Corporation

PreviewView

Jul31

ENBBMO

Company Snapshot

IDEXX Laboratories, Inc. is a leading provider of diagnostic products and services for the veterinary, livestock, and poultry markets....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and growth potential, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and product offerings, crucial for sustaining long-term growth.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IDXX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+2.46%

Avg Stock Reaction

+6.39%

Last Quarter Recap

In Q1-2026, IDEXX reported an EPS of $3.47, exceeding estimates by 1.49%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Focus on expanding product lines in veterinary diagnostics.
Commitment to enhancing customer service and support.
Plans to invest in research and development for innovative solutions.

Expectations

Wall Street Expectations

Overall expectations for IDEXX's upcoming earnings are mixed, with investors looking for signs of continued growth in a competitive market.

Bull Case

If IDEXX can demonstrate strong revenue growth and maintain or improve its EPS, it could signal robust demand for its products, leading to a positive market reaction.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported revenue growth in the veterinary diagnostics segment?

This metric is crucial as it directly impacts overall profitability and investor confidence in IDEXX's growth trajectory.

Will the EPS exceed $3.50?

Exceeding this EPS threshold could indicate strong operational performance and boost market sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate IDEXX's ability to leverage its innovative product pipeline, which could drive higher-than-expected revenue growth this quarter.

Supporting Evidence

The company's recent investments in R&D are likely to yield new products that could boost sales.

Historical performance shows a strong beat rate of 75%, indicating a tendency to exceed expectations.

Options pricing suggests a significant move, which may indicate that traders are anticipating a positive surprise.

Key Risk

If veterinary diagnostic sales exceed expectations, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around IDEXX's ability to maintain growth in a competitive market while managing costs effectively.

Bull Confirmed If

Revenue growth of over 10% year-over-year would confirm the bull case.

Bear Confirmed If

Any revenue decline or stagnant growth would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±17.90%

Historical Avg

±10.0%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect notable volatility around the earnings announcement.

Options are pricing ±17.9% while IDXX has averaged ±10.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

31.3%

Calls (3K)P/C Ratio: 2.14Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If IDEXX beats expectations, history suggests a potential stock increase of around +8.77%, confirming strong demand and operational efficiency.

In-Line / Cautious

An in-line report may lead to a muted reaction, with investors closely analyzing management's commentary for future guidance.

Miss

If the company misses expectations, history suggests a potential decline of around -0.73%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches in the veterinary diagnostics space.
2Any commentary on market share changes or competitive dynamics.
3Insights into cost management strategies and their impact on margins.
4Details on customer feedback regarding recent product innovations.
5Guidance on future revenue expectations and growth strategies.